Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054119 · ClinicalTrials.gov registry record · Phase 2
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00054119 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 27 participants.
The verdict
NCT00054119, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of karenitecin in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer that has not responded to platinum-based treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- OTHER Pharmacological Study
- DRUG Cositecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054119
The ClinicalTrials.gov registry entry for NCT00054119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacological Study is the first listed.
NCT00054119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054119 about?
NCT00054119 is a clinical study titled "Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Phase II trial to study the effectiveness of karenitecin in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer that has not responded to platinum-based treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so...
What is the current status of trial NCT00054119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2003-01.
What interventions are being tested in trial NCT00054119?
The interventions under investigation include: Pharmacological Study (OTHER), Cositecan (DRUG).
Who is sponsoring clinical trial NCT00054119?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.